(Q38159801)

English

Immune modulation in cancer with antibodies

scientific article published on 30 October 2013

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

30 August 2017

Immune modulation in cancer with antibodies (English)

1 reference

stated in

Europe PubMed Central

30 August 2017

1 reference

4

James P Allison

0 references

Jedd D. Wolchok

series ordinal

5

object named as

Jedd D Wolchok

1 reference

stated in

Europe PubMed Central

30 August 2017

David B Page

1

1 reference

stated in

Europe PubMed Central

PubMed ID

24188664

retrieved

30 August 2017

Michael A Postow

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed ID

24188664

retrieved

30 August 2017

Margaret K Callahan

series ordinal

3

1 reference

stated in

Europe PubMed Central

30 August 2017

30 October 2013

1 reference

stated in

Europe PubMed Central

30 August 2017

Annual Review of Medicine

1 reference

stated in

Europe PubMed Central

30 August 2017

65

1 reference

stated in

Europe PubMed Central

30 August 2017

185-202

1 reference

stated in

Europe PubMed Central

30 August 2017

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

MHC class I molecules and KIRs in human history, health and survival

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Modulation of GITR for cancer immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Prostate cancer immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Advances in the treatment of metastatic melanoma: adoptive T-cell therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Trafficking of immune cells in the central nervous system

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Immunotherapy of cancer with 4-1BB.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab for patients with advanced mucosal melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Agonistic CD40 antibodies and cancer therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Agonist antibodies to TNFR molecules that costimulate T and NK cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

An immune-active tumor microenvironment favors clinical response to ipilimumab

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab-induced acute severe colitis treated by infliximab.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

The treatment of brain metastases in melanoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Combining immunotherapy and targeted therapies in cancer treatment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-MED-092012-112807

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2006.24.18_SUPPL.4609

Identifiers

DOI

10.1146/ANNUREV-MED-092012-112807

1 reference

stated in

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

PubMed ID

24188664

retrieved

30 August 2017

(Q38159801)

Immune modulation in cancer with antibodies

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)